The improved survival with sipuleucel-T, an autologous antigen-presenting cell-based agent, for the treatment of patients with metastatic asymptomatic and minimally symptomatic castration-resistant prostate cancer supports immunotherapy as a valid approach.
Also, multiple novel immunotherapeutic approaches are undergoing vigorous investigation. T-lymphocyte checkpoint blockade and poxvirus-based prime-boost approaches are in phase III evaluation. Other immunotherapeutic platforms undergoing early investigation include radioimmunoconjugates and adenovirus-based, DNA-based, and Listeria-based approaches. The development of predictive markers for immune response that translate into improved long-term outcomes is important. This article reviews the emerging data and the unique strengths and weaknesses of these approaches.
Written by:
Sonpavde G, Kantoff PW. Are you the author?
Department of Medicine, Section of Medical Oncology, University of Alabama at Birmingham (UAB) Comprehensive Cancer Center, 1802 6th Avenue South, WTI-520A, Birmingham, AL 35294, USA.
Reference: Urol Clin North Am. 2012 Nov;39(4):465-81.
doi: 10.1016/j.ucl.2012.07.004
PubMed Abstract
PMID: 23084524
UroToday.com Prostate Cancer Section
